

7231 Parkway Drive, Suite 100, Hanover, MD 21076

FAX Completed Form and Applicable Progress Notes to:

(410) 424-4037

I.

USFHP Pharmacy Prior Authorization Form

for ruxolitinib cream (Opzelura)

To be completed by Requesting provider			
Drug Name:	Strength:		
	I		
Dosage/Frequency (SIG):	Duration of Therapy:		

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step	Please complete patient and physician information (please print):					
.1	Patient Name: Ph	ysician Name:				
	Address: Address:					
	Sponsor ID #	Phone #:				
Ston	Date of Birth: Secure Fax #:					
Step	Please complete the clinical assessment:					
2	1. Has the patient received this medication under the TRICARE benefit in the last 6 months? <i>Please choose</i>	🗆 Yes	🗆 No			
	"No" if the patient did not previously have a TRICARE approved PA for Opzelura.	Proceed to question 2	Proceed to question 4			
	2. Has the patient had a positive response to therapy, for example, an Investigator's Static Global	□ Yes	🗆 No			
	Assessment (ISGA) score of clear (0) or almost	Proceed to question 3	STOP			
	clear?		Cov erage not approv ed			
	3. Has the patient's disease severity improved and	□ Yes	🗆 No			
	stabilized to warrant continued therapy?	Sign and date below	STOP			
			Cov erage not approv ed			
	4. What is the indication or diagnosis?	☐ Mild to moderate or uncontrolled atopic dermatitis - Proceed to question 5				
		□ Other - STOP Coverage not approved				
	5. Is the patient 12 years of age or older?	□ Yes	🗆 No			
		Proceed to question 6	STOP			
			Cov erage not approv ed			
	6. Is the requested medication being prescribed by a	□ Yes	🗆 No			
	dermatologist, allergist, or immunologist?	Proceed to question 7	STOP			
			Cov erage not approv ed			
	7. How old is the patient?	□ 18 years of age or older - Proceed to question 8				
		□ 12 to 17 years of age – Proceed to question 9				

8.	Does the patient have a contraindication to, intolerability to, or have they failed treatment with	□ Yes	□ No
	one medication in the following category: topical	Proceed to question 10	STOP
corticosteroids - high potency/class 1 topical corticosteroid (for example, clobetasol propionate 0.05% ointment/cream, fluocinonide 0.05% ointment/cream)?		Coverage not approved	
9.	······································	□ Yes	□ No
	intolerability to, or have they failed treatment with one medication in the following category: topical	Proceed to question 10	STOP
	corticosteroids, can be any topical corticosteroid, including low potency steroids?		Coverage not approved
10.	Does the patient have a contraindication to,	□ Yes	□ No
	intolerability to, or have they failed treatment with one medication in the following category: topical	Proceed to question 11	STOP
	calcineurin inhibitor (for example, pimecrolimus, tacrolimus)?		Coverage not approved
	Is the patient using other immunobiolgics	□ Yes	□ No
	concomitantly (for example, Humira, Stelara etc), other JAK inhibitors (for example, Xeljanz, Olumiant, STOP	STOP	Sign and date below
	Rinvoq), or potent immunosuppressants such as azathioprine or cyclosporine?	Cov erage not approv ed	

Step 3

Prescriber Signature

Date

[02 March 2022]

For Internal Use Only		
Approved:	Duration of Approval:month(s)	
Denied:	Authorized By:	
]Incomplete/Other:	PA#:	
Date Faxed to MD:	Date Decision Rendered:	